Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 16, 2009 | Chief Scientific Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 80,000 | -- | 80,000 | |
| Feb 03, 2009 | Chief Scientific Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 54,000 | -- | 54,000 | |
| Jun 10, 2008 | Chief Scientific Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,000 | -- | 20,000 | |
| Feb 05, 2008 | Chief Scientific Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 45,000 | -- | 45,000 | |
| May 30, 2007 | Chief Scientific Officer | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| May 30, 2007 | Chief Scientific Officer | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| May 30, 2007 | Chief Scientific Officer | Initial Statement of Beneficial Ownership of Securities | Form 3 | -- | -- | -- | |
| Apr 06, 2021 | Chief Science Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,501 | -- | 448,617 | |
| Jan 15, 2021 | Chief Science Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 22,458 | -- | 438,076 | |
| Jan 15, 2021 | Chief Science Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 9,960 | $21.84 | 428,116 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.